Literature DB >> 2793874

Notes to applicants for marketing authorizations on the production and quality control of medicinal products derived by recombinant DNA technology. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.

.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2793874     DOI： 10.1016/0092-1157(89)90014-0

Source DB:  PubMed          Journal:  J Biol Stand        ISSN： 0092-1157


× No keyword cloud information.
  1 in total

1.  Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII.

Authors:  J P Betts
Journal:  BMJ       Date:  1998-05-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.